Low-dose oral methotrexate management of patients with bilateral Meniere's disease

Ear, Nose and Throat Journal

Volumn 79, Issue 2, 2000, Pages 82-92

  Kilpatrick, Jefferson K ^a   Sismanis, Aristides ^a,b   Spencer, Robert F ^a   Wise, Christopher M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dept Otolaryngol Hd Neck Surg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MENIERE DISEASE; TINNITUS; TREATMENT OUTCOME; VERTIGO;

EID: 0034000315     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556130007900207     Document Type: Article

References (41)

1. Langman AW, Kemink JL, Graham MD. Titration streptomycin therapy for bilateral Ménière's disease: Follow-up report. Ann Otol Rhinol Laryngol 1990;99:923-6.
2. Shea JJ, Ge X, Orchik DJ. Long-term results of low dose intramuscular streptomycin for Ménière's disease. Am J Otol 1994;15 540-4.
3. Fowler EP. Streptomycin treatment for vertigo. Trans Am Acad Ophthalmol Otolaryngol 1948;52:293-301
4. Graham MD. Bilateral Ménière's disease: Treatment with intramuscular titration streptomycin sulfate. Otolaryngol Clin North Am 1997;30:1097-100.
5. Wilson WR, Schuknecht HF. Update on the use of streptomycin therapy for Ménière's disease. Am J Otol 1980;2:108-11.
6. Harris JP, Darmstadt GL. Sensorineural hearing loss: Medical therapy. In: Gates G, ed. Current Therapy in Otolaryngology Head and Neck Surgery. Vol 4. Philadelphia: B.C. Decker, 1990:50-6.
7. O'Dell JR. Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:779-96.
8. Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997;23:841-53.
9. Wilke WS. Methotrexate use in miscellaneous inflammatory diseases. Rheum Dis Clin North Am 1997;23:855-82.
10. Sismanis A, Thompson T, Willis HE Methotrexate therapy for autoimmune hearing loss: A preliminary report Laryngoscope 1994;104:932-4.
11. Sismanis A, Wise CM, Johnson GD. Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg 1997;116:146-52.
12. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
13. McCabe BF Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;88:585-9.
14. Hughes GB, Kinney SE, Barna BP, Calabrese LH. Autoimmune reactivity in Ménière's disease. A preliminary report. Laryngoscope 1983;93:410-7.
15. Brookes GB. Circulating immune complexes in Ménière's disease. Arch Otolaryngol Head Neck Surg 1986;112:536-40.
16. Tomiyama S, Harris JP. The role of the endolymphatic sac in inner ear immunity. Acta Otolaryngol 1987;103:182-8.
17. Dornhoffer JL, Waner M, Arenberg IK, Montague D. Immunoperoxidase study of the endolymphatic sac in Ménière's disease. Laryngoscope 1993;103:1027-34.
18. Dornhoffer JL, Arenberg IK. Immune mechanisms in Ménière's syndrome. Otolaryngol Clin North Am 1997;30:1017-26.
19. Hughes GB, Moscicki R, Barna BP, San Martin JE. Laboratory diagnosis of immune inner ear disease. Am J Otol 1994;15:198-202.
20. Harris JP, Sharp PA. Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope 1990;100:516-24.
21. Moscicki RA, San Martin JE, Quintero CH, et at. Serum antibody to inner ear proteins in patients with progressive hearing loss: Correlation to disease activity and response to corticosteroid treatment. JAMA 1994;272:611-6.
22. McCabe BF. Autoimmune inner ear disease: Results of therapy. Adv Otorhinolaryngol 1991;46:78-81.
23. Larouere MJ, Kartush JM. Ménière's disease: Surgical therapy. In: Gates G, ed. Current Therapy in Otolaryngology Head and Neck Surgery. 6th ed. St. Louis: Mosby Year-Book, 1997:81-6.
24. Pyykko I, Ishizaki H, Kaasinen S, Aalto H. Intratympanic gentamicin in bilateral Ménière's disease. Otolaryngol Head Neck Surg 1994;110:162-7.
25. Luetje CM. Theoretical and practical implications for plasmapheresis in autoimmune inner ear disease. Laryngoscope 1989;99:1137-46.
26. Hughes GB, Barna BP, Kinney SE, et al. Immune inner ear disease: 1990 report Trans Am Otol Soc 1990;78:86-91.
27. Fauci AS, Wolff SM. Wegener's granulomatosis: Studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973;52:535-61.
28. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis: Clinical, pathologic, immunologie and therapeutic considerations. Ann Intern Med 1978;89:660-76.
29. Harris JP. Autoimmune diseases affecting the inner ear. Adv Otolaryngol Head Neck Surg 1993;7:59-77.
30. Physicians' Desk Reference. 49th ed. Montvale, N.J.: Medical Economics Co., 1995:1165-9.
31. Weinblatt ME. Methotrexate for chronic diseases in adults. N Engl J Med 1995;332:330-1.
32. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7
33. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis N Engl J Med 1985;312:818-22
34. Giannini EH, Brewer EJ, Kuzmina N, et al Methotrexate in resistant juvenile rheumatoid arthritis Results of the U.S.A.- U.S.S.R double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
35. Mullarkey MF, Blumenstein BA, Andrade WP, et al. Methotrexate in the treatment of corticosteroid-dependent asthma: A double-blind crossover study. N Engl J Med 1988;318:603-7.
36. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum 1992;35:129-37.
37. Scully CJ, Anderson CJ, Cannon GW. Long-term methotrexate therapy for rheumatoid arthritis. Semin Arthritis Rheum 1991;20:317-31.
38. Walker AM, Funch D, Dreyer NA, et al Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993;36:329-35.
39. Bennet DR. Antiarthritic drugs. In: Drug Evaluations Annual, 1991. Chicago: American Medical Association, 1991:1722-3.
40. Kremer JM, Alarcon GS, Lightfoot RW Jr., et al. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
41. Weinblatt ME, Maier AL. Longterm experience with low dose weekly methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1990;22:33-8.